Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Overexpression”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Large-scale testing (Phase 3)Not Yet RecruitingNCT06908772
What this trial is testing

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Who this might be right for
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Shanghai JMT-Bio Inc. 390
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT00294762
What this trial is testing

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
OSI Pharmaceuticals 143
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07323641
What this trial is testing

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT02748213
What this trial is testing

Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Testing effectiveness (Phase 2)UnknownNCT04880811
What this trial is testing

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 43
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Not applicableUnknownNCT02136836
What this trial is testing

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Who this might be right for
Stomach Neoplasms
Yonsei University 860
Testing effectiveness (Phase 2)Looking for participantsNCT05777278
What this trial is testing

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 29
Testing effectiveness (Phase 2)Study completedNCT02205047
What this trial is testing

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Malignant Neoplasm of StomachMalignant Neoplasm of Cardio-esophageal Junction of StomachEpidermal Growth Factor Receptor (EGFR) Protein Overexpression
European Organisation for Research and Treatment of Cancer - EORTC 172
Testing effectiveness (Phase 2)UnknownNCT03940976
What this trial is testing

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06343064
What this trial is testing

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 156
Early research (Phase 1)UnknownNCT04976218
What this trial is testing

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Who this might be right for
Solid Tumor, AdultEGFR Overexpression
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03329690
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Who this might be right for
Neoplasm, Gastrointestinal
Daiichi Sankyo Co., Ltd. 233
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Testing effectiveness (Phase 2)Looking for participantsNCT06975410
What this trial is testing

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Who this might be right for
EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
Yuhan Corporation 80
Early research (Phase 1)Study completedNCT01255657
What this trial is testing

ABT-806 in Subjects With Advanced Solid Tumor Types

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 49
Early research (Phase 1)Study completedNCT00906698
What this trial is testing

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Who this might be right for
Neoplasms
Boehringer Ingelheim 55
Load More Results